First-in-India experience with 90Y-BhabhaSphere: an indigenous 90Y-TheraSphere biosimilar for transarterial radioembolization of hepatic malignancies
This study highlights a key advantage of 90Y-BhabhaSphere: its significantly higher specific activity (approximately 6000 Bq/sphere) compared to commercially available 90Y-TheraSphere (2700 Bq/sphere). This suggests a potential for delivering higher tumour doses while minimizing radiation exposure to healthy liver tissue, thereby reducing the risk of radiation-induced liver damage.
Authors
- Sharad P. Lohar
- Ameya D. Puranik (ORCID: https://orcid.org/0000-0001-6125-992X)
- Usha Pandey (ORCID: https://orcid.org/0000-0003-0555-9930)
- Venkatesh Rangarajan (ORCID: https://orcid.org/0000-0003-2581-3086)
- Sudipta Chakraborty (ORCID: https://orcid.org/0000-0002-8002-439X)
- Kunal Gala (ORCID: https://orcid.org/0000-0002-7794-8831)
- Basant K. Tiwary (ORCID: https://orcid.org/0000-0002-8194-5860)
- Anupam Mathur (ORCID: https://orcid.org/0000-0003-2619-001X)
- Suyash Sureshchandra Kulkarni (ORCID: https://orcid.org/0000-0001-5972-6111)
- Ashish Kumar Jha (ORCID: https://orcid.org/0000-0001-5998-3206)
- Nilendu Purandare
- AlkaMary Mathai
- A. Rajeswari
- Aaditya Shah
- K.V. Vimalnath
- Nitin Sudhakar Shetye
Institutions
- Bhabha Atomic Research Centre (IN)
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
- Indian Navy (IN)
- Bhabha Atomic Research Center Hospital (IN)
Publication Details
- Journal
- British Journal of Radiology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1093/bjr/tqaf197
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00